TD Cowen analyst Ritu Baral maintains $Neurogene (NGNE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 52.1% and a total average return of 17.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
Preliminary data from the Phase 1/2 study of NGN-401 suggests a distinct efficacy signal, demonstrating what appears to be genuine clinical improvements in 4 pediatric patients with Rett syndrome. The primary concern may revolve around the serious adverse event (SAE) observed at the higher dosage of NGN-401 and the associated risk profile for the treatment program. Although details about this SAE are limited due to recent awareness, it is noted that the observed efficacy of NGN-401 has been at the lower dose, which to date seems to have a relatively safe profile.
The validation of NGN-401 in Rett syndrome through the company's Phase 1/2 readout highlighted unprecedented and potentially approvable efficacy, along with favorable safety at a low dosage. However, the analyst notes that investor attention was drawn to the uncertainty surrounding a serious adverse event that occurred in the high dosage cohort.
The firm expressed optimism regarding Neurogene's stock following the company's announcement of initial interim clinical data for its gene therapy NGN-401 in Rett syndrome. The analyst believes that the efficacy data is more likely than not sufficient to support approval.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
